The Latest Breaking News from Immunogen

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

Immunogen sees its Relative Strength Rating reach the elite 90-plus level.

According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million.

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.

  Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-0.21.

  Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen reported an EPS of $-0.17.

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-1.71.